Cargando…

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus

BACKGROUND: Established mouse models of HER2+ cancer are based on the over-expression of rodent Neu/Erbb2 homologues, which are incompatible with human HER2 (huHER2) targeted therapeutics. Additionally, the use of immune-deficient xenograft or transgenic models precludes assessment of native anti-tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taha, Zaid, Crupi, Mathieu J.F., Alluqmani, Nouf, Fareez, Faiha, Ng, Kristy, Sobh, Judy, Lee, Emily, Chen, Andrew, Thomson, Max, Spinelli, Marcus M., Ilkow, Carolina S., Bell, John C., Arulanandam, Rozanne, Diallo, Jean-Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154558/ https://www.ncbi.nlm.nih.gov/pubmed/37153626 http://dx.doi.org/10.3389/fimmu.2023.1181014

Ejemplares similares

The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
por: Arulanandam, Rozanne, et al.
Publicado: (2020)

Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy
por: Wong, Boaz, et al.
Publicado: (2022)

Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
por: Alluqmani, Nouf, et al.
Publicado: (2022)

Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)

Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry
por: Azad, Taha, et al.
Publicado: (2021)

SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition
por: Azad, Taha, et al.
Publicado: (2021)

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
por: Tzelepis, Fanny, et al.
Publicado: (2020)

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
por: Crupi, Mathieu J. F., et al.
Publicado: (2022)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
por: Sharp, Adam, et al.
Publicado: (2015)

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
por: Corbin, Kimberly S., et al.
Publicado: (2020)

Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
por: Sella, Tal, et al.
Publicado: (2022)

Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
por: Liu, Fen, et al.
Publicado: (2023)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
por: Chen, Liuxi, et al.
Publicado: (2016)

Genetic Relatedness of Dolphin Rhabdovirus with Fish Rhabdoviruses
por: Siegers, Jurre Y., et al.
Publicado: (2014)

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
por: Boulton, Stephen, et al.
Publicado: (2023)

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes
por: Naumenko, Victor, et al.
Publicado: (2022)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
por: Egloff, Heidi, et al.
Publicado: (2018)

Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
por: Manthri, Sukesh, et al.
Publicado: (2019)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
por: Engebraaten, Olav, et al.
Publicado: (2021)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
por: Moghaddas, Azadeh, et al.
Publicado: (2016)

Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
por: Prete, Salvatore Del, et al.
Publicado: (2020)

Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis
por: Cobert, Amani M., et al.
Publicado: (2020)

Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients—sequentially, or better simultaneously?
por: Piroth, Marc D., et al.
Publicado: (2020)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
por: Hakroush, Samy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ki8f316esevkd2hukss9fpgd1q